"We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. From April 2004 to August 2008,. of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%)."@en . . . . "Reiter, A." . "Klingebiel, T." . . "11130" . . . "7"^^ . . "Schrappe, M." . "Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia"@en . . . . "000279254300005" . . "Janka-Schaub, G." . . "acute-lymphoblastic-leukemia; chemotherapy plus rituximab; randomized controlled-trial; childrens oncology group; central-nervous-system; elderly-patients; induced apoptosis; clinical-trials; r-chop; adolescents"@en . "[4D2B363A1AD8]" . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "1"^^ . "19" . "Journal of Clinical Oncology" . "RIV/00216208:11130/10:6264!RIV11-MZ0-11130___" . "14"^^ . "0732-183X" . . . "Burkhardt, B." . . "Klapper, W." . . "Attarbaschi, A." . . "Kontny, U." . . "RIV/00216208:11130/10:6264" . "Klein, C." . "Borkhardt, A." . "Kab\u00ED\u010Dkov\u00E1, Edita" . . . "Meinhardt, A." . . "Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia" . "We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. From April 2004 to August 2008,. of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%)." . "P(NS9997), Z(MZ0FNM2005)" . "Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia"@en . "28" . "278725" . "Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia" . "Berthold, F." . . "Zimmermann, M." .